This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Novartis Ag, University of Pennsylvania. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3,978 
1 out of 2,659 
Years Active: 2022
Title: Jihyun Lee: Innovator in Cancer Treatment Technologies
Introduction
Jihyun Lee is a notable inventor based in Wynnewood, PA, who has made significant contributions to the field of cancer treatment. With a focus on innovative therapies, Lee has developed a patented technology that enhances the effectiveness of chimeric antigen receptors (CARs) in targeting tumor antigens.
Latest Patents
Lee holds a patent for "Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor." This invention provides compositions and methods for treating diseases associated with the expression of a tumor antigen. It includes nucleic acids that comprise a truncated PGK promoter operably linked to a CAR specific to a tumor antigen. The patent also covers vectors encoding these elements and recombinant T cells that express the CARs. Furthermore, it outlines methods for administering genetically modified T cells that express a CAR with an antigen-binding domain targeting tumor antigens.
Career Highlights
Throughout his career, Jihyun Lee has worked with prominent organizations such as Novartis and the University of Pennsylvania. His experience in these institutions has allowed him to collaborate on groundbreaking research and development in the field of immunotherapy.
Collaborations
Lee has collaborated with notable colleagues, including Jennifer Brogdon and Hilmar Erhard Ebersbach. These partnerships have contributed to the advancement of his research
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile